The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in prospectively-selected subjects with genetically-defined tumors that harbor genomic alterations linked to increased replication stress and that are hypothesized to be more sensitive to checkpoint kinase 1 (Chk1) inhibition via synthetic lethality. Specific cancer indications that frequently harbor these genetic mutations will be studied.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Subjects With Adverse Events as Assessed by CTCAE 4.03
Timeframe: Up to 30 days after last dose of SRA737
Maximum Tolerated Dose of SRA737
Timeframe: Cycle 1 (28 days) in the Dose Escalation Phase
Recommended Phase 2 Dose of SRA737
Timeframe: Up to 30 days after last dose of SRA737
Disease Control Rate (DCR) of SRA737
Timeframe: Radiographic tumor assessments were performed every 2 cycles of therapy.
Time to Progression (TTP)
Timeframe: Radiographic tumor assessments were performed every 2 cycles of therapy. Follow-up assessments were made every 16 weeks for subjects who had not progressed and had not initiated new anticancer therapy.
Progression Free Survival (PFS)
Timeframe: Radiographic tumor assessments were performed every 2 cycles of therapy. Follow-up assessments were made every 16 weeks for subjects who had not progressed and had not initiated new anticancer therapy.
Overall Survival (OS)
Timeframe: Follow-up assessments were made every 16 weeks for subjects who had not progressed and had not initiated new anticancer therapy.